{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:11:13Z","timestamp":1749701473741,"version":"3.41.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"scPharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40262-025-01515-2","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:35:07Z","timestamp":1747164907000},"page":"899-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Adult Population Pharmacokinetic Model to Simulate Subcutaneous Administration of a Fixed Dose of Furosemide in Adolescents with Heart Failure and Volume Overload"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-8759","authenticated-orcid":false,"given":"Christoph P.","family":"Hornik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5973-2579","authenticated-orcid":false,"given":"Henry P.","family":"Foote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Kendig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0746-4110","authenticated-orcid":false,"given":"John","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"7","key":"1515_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/children5070088","volume":"5","author":"BB Das","year":"2018","unstructured":"Das BB. Current state of pediatric heart failure. Children (Basel). 2018;5(7):88. https:\/\/doi.org\/10.3390\/children5070088.","journal-title":"Children (Basel)"},{"issue":"6","key":"1515_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cardfail.2012.03.001","volume":"18","author":"JW Rossano","year":"2012","unstructured":"Rossano JW, Kim JJ, Decker JA, et al. Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. J Card Fail. 2012;18(6):459\u201370. https:\/\/doi.org\/10.1016\/j.cardfail.2012.03.001.","journal-title":"J Card Fail"},{"key":"1515_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ahj.2018.11.010","volume":"209","author":"DS Burstein","year":"2019","unstructured":"Burstein DS, Shamszad P, Dai D, et al. Significant mortality, morbidity and resource utilization associated with advanced heart failure in congenital heart disease in children and young adults. Am Heart J. 2019;209:9\u201319. https:\/\/doi.org\/10.1016\/j.ahj.2018.11.010.","journal-title":"Am Heart J"},{"issue":"19","key":"1515_CR4","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2022.03.336","volume":"79","author":"S Amdani","year":"2022","unstructured":"Amdani S, Marino BS, Rossano J, Lopez R, Schold JD, Tang WHW. Burden of pediatric heart failure in the United States. J Am Coll Cardiol. 2022;79(19):1917\u201328. https:\/\/doi.org\/10.1016\/j.jacc.2022.03.336.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"1515_CR5","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"issue":"7","key":"1515_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/children11070859","volume":"11","author":"BB Das","year":"2024","unstructured":"Das BB. A review of contemporary and future pharmacotherapy for chronic heart failure in children. Children (Basel). 2024;11(7):859. https:\/\/doi.org\/10.3390\/children11070859.","journal-title":"Children (Basel)"},{"issue":"2","key":"1515_CR7","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1161\/CIR.0000000000001245","volume":"150","author":"S Amdani","year":"2024","unstructured":"Amdani S, Conway J, George K, et al. Evaluation and management of chronic heart failure in children and adolescents with congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2024;150(2):e33\u201350. https:\/\/doi.org\/10.1161\/CIR.0000000000001245.","journal-title":"Circulation"},{"issue":"7","key":"1515_CR8","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.3390\/jcm12072611","volume":"12","author":"B Castaldi","year":"2023","unstructured":"Castaldi B, Cuppini E, Fumanelli J, et al. Chronic heart failure in children: state of the art and new perspectives. J Clin Med. 2023;12(7):2611. https:\/\/doi.org\/10.3390\/jcm12072611.","journal-title":"J Clin Med"},{"key":"1515_CR9","unstructured":"FUROSEMIDE INJECTION\u00ae (furosemide). Lake Forest, IL: Hospira; 2024."},{"issue":"1","key":"1515_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.21037\/cdt-20-358","volume":"11","author":"H Ahmed","year":"2021","unstructured":"Ahmed H, VanderPluym C. Medical management of pediatric heart failure. Cardiovasc Diagn Ther. 2021;11(1):323\u201335. https:\/\/doi.org\/10.21037\/cdt-20-358.","journal-title":"Cardiovasc Diagn Ther"},{"key":"1515_CR11","unstructured":"FUROSCIX\u00ae (furosemide injection). Burlington, MA: scPharmaceuticals; 2025."},{"issue":"1","key":"1515_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jacbts.2017.10.001","volume":"3","author":"DA Sica","year":"2018","unstructured":"Sica DA, Muntendam P, Myers RL, et al. Subcutaneous furosemide in heart failure: pharmacokinetic characteristics of a newly buffered solution. JACC Basic Transl Sci. 2018;3(1):25\u201334. https:\/\/doi.org\/10.1016\/j.jacbts.2017.10.001.","journal-title":"JACC Basic Transl Sci"},{"key":"1515_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.07.015","author":"MA Konstam","year":"2024","unstructured":"Konstam MA, Massaro J, Dhingra R, et al. Avoiding treatment in hospital with subcutaneous furosemide for worsening heart failure. JACC Heart Fail. 2024. https:\/\/doi.org\/10.1016\/j.jchf.2024.07.015.","journal-title":"JACC Heart Fail"},{"key":"1515_CR14","unstructured":"On-Body Infusor for FUROSCIX\u00ae instructions for use. Burlington, MA: scPharmaceuticals; 2024."},{"issue":"5","key":"1515_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00003088-199018050-00004","volume":"18","author":"LL Ponto","year":"1990","unstructured":"Ponto LL, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (Part I). Clin Pharmacokinet. 1990;18(5):381\u2013408. https:\/\/doi.org\/10.2165\/00003088-199018050-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1515_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341. https:\/\/doi.org\/10.1159\/000180580.","journal-title":"Nephron"},{"key":"1515_CR17","unstructured":"The Comprehensive R Archive Network. Institute for Statistics and Mathematics of WU (Wirtschaftsuniversit\u00e4t Wien). https:\/\/cran.r-project.org\/. Accessed August 27, 2024."},{"issue":"3","key":"1515_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.pharep.2017.01.006","volume":"69","author":"D Kodati","year":"2017","unstructured":"Kodati D, Yellu N. Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions. Pharmacol Rep. 2017;69(3):492\u20136. https:\/\/doi.org\/10.1016\/j.pharep.2017.01.006.","journal-title":"Pharmacol Rep"},{"key":"1515_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ejps.2017.08.009","volume":"109","author":"M Shukla","year":"2017","unstructured":"Shukla M, Ibrahim MMA, Jain M, et al. Model based population PK-PD analysis of furosemide for BP lowering effect: a comparative study in primary and secondary hypertension. Eur J Pharm Sci. 2017;109:253\u201361. https:\/\/doi.org\/10.1016\/j.ejps.2017.08.009.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"1515_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/11596620-000000000-00000","volume":"14","author":"GM Pacifici","year":"2012","unstructured":"Pacifici GM. Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants. Paediatr Drugs. 2012;14(4):233\u201346. https:\/\/doi.org\/10.2165\/11596620-000000000-00000.","journal-title":"Paediatr Drugs"},{"issue":"4","key":"1515_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/00045391-200107000-00010","volume":"8","author":"J Prandota","year":"2001","unstructured":"Prandota J. Clinical pharmacology of furosemide in children: a supplement. Am J Ther. 2001;8(4):275\u201389. https:\/\/doi.org\/10.1097\/00045391-200107000-00010.","journal-title":"Am J Ther"},{"issue":"1","key":"1515_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF00561400","volume":"12","author":"F Andreasen","year":"1977","unstructured":"Andreasen F, Mikkelsen E. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol. 1977;12(1):15\u201322. https:\/\/doi.org\/10.1007\/BF00561400.","journal-title":"Eur J Clin Pharmacol"},{"issue":"16","key":"1515_CR23","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840\u201378. https:\/\/doi.org\/10.1161\/CIR.0000000000000664.","journal-title":"Circulation"},{"issue":"6","key":"1515_CR24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00467-012-2251-4","volume":"28","author":"JL Jefferies","year":"2013","unstructured":"Jefferies JL, Goldstein SL. Cardiorenal [corrected] syndrome: an emerging problem in pediatric critical care. Pediatr Nephrol. 2013;28(6):855\u201362. https:\/\/doi.org\/10.1007\/s00467-012-2251-4.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1515_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/BF02082332","volume":"3","author":"TP Green","year":"1982","unstructured":"Green TP, Mirkin BL. Determinants of the diuretic response to furosemide in infants with congestive heart failure. Pediatr Cardiol. 1982;3(1):47\u201351. https:\/\/doi.org\/10.1007\/BF02082332.","journal-title":"Pediatr Cardiol"},{"issue":"4","key":"1515_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF00265840","volume":"40","author":"J Prandota","year":"1991","unstructured":"Prandota J, Smith IJ, Hilman BC, Wilson JT. Diuretic effect and disposition of furosemide in cystic fibrosis. Eur J Clin Pharmacol. 1991;40(4):333\u201341. https:\/\/doi.org\/10.1007\/BF00265840.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"1515_CR27","first-page":"598","volume":"21","author":"G Gonz\u00e1lez-Martin","year":"1983","unstructured":"Gonz\u00e1lez-Martin G, Bravo I, Ibarra N, Arancibia A. Clinical pharmacokinetics of furosemide in children with nephrotic syndrome. Int J Clin Pharmacol Ther Toxicol. 1983;21(12):598\u2013601.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"4","key":"1515_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF00637617","volume":"21","author":"E Riva","year":"1982","unstructured":"Riva E, Fossali E, Bettinelli A. Kinetics of furosemide in children with chronic renal failure undergoing regular haemodialysis. Eur J Clin Pharmacol. 1982;21(4):303\u20136. https:\/\/doi.org\/10.1007\/BF00637617.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1515_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","volume":"30","author":"NH Holford","year":"1996","unstructured":"Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30(5):329\u201332. https:\/\/doi.org\/10.2165\/00003088-199630050-00001.","journal-title":"Clin Pharmacokinet"},{"key":"1515_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3733\/hilg.v06n11p315","volume":"6","author":"M Kleiber","year":"1932","unstructured":"Kleiber M. Body size and metabolism. Hilgardia. 1932;6:315\u201353.","journal-title":"Hilgardia"},{"issue":"4","key":"1515_CR31","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bcp.13160","volume":"83","author":"E Germovsek","year":"2017","unstructured":"Germovsek E, Barker CI, Sharland M, Standing JF. Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful? Br J Clin Pharmacol. 2017;83(4):777\u201390. https:\/\/doi.org\/10.1111\/bcp.13160.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1515_CR32","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941\u201352. https:\/\/doi.org\/10.1002\/jps.23574.","journal-title":"J Pharm Sci"},{"issue":"6","key":"1515_CR33","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/0009-9236(95)90021-7","volume":"58","author":"JN van den Anker","year":"1995","unstructured":"van den Anker JN, Schoemaker RC, Hop WC, et al. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther. 1995;58(6):650\u20139. https:\/\/doi.org\/10.1016\/0009-9236(95)90021-7.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1515_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-199019010-00001","volume":"19","author":"JT Gilman","year":"1990","unstructured":"Gilman JT. Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications. Clin Pharmacokinet. 1990;19(1):1\u201310. https:\/\/doi.org\/10.2165\/00003088-199019010-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1515_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1185\/146300906778876170","volume":"6","author":"A Edginton","year":"2006","unstructured":"Edginton A, Willmann S. Physiology-based versus allometric scaling of clearance in children; an eliminating process based comparison. Paedieatr Perinatal Drug Ther. 2006;6(7):146\u201353. https:\/\/doi.org\/10.1185\/146300906778876170.","journal-title":"Paedieatr Perinatal Drug Ther"},{"issue":"9","key":"1515_CR36","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931\u201356. https:\/\/doi.org\/10.2165\/00003088-200645090-00005.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1515_CR37","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/s0022-3476(78)80133-4","volume":"92","author":"BS Arant Jr","year":"1978","unstructured":"Arant BS Jr. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr. 1978;92(5):705\u201312. https:\/\/doi.org\/10.1016\/s0022-3476(78)80133-4.","journal-title":"J Pediatr"},{"issue":"12","key":"1515_CR38","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157\u201367. https:\/\/doi.org\/10.1056\/NEJMra035092.","journal-title":"N Engl J Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01515-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01515-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01515-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T13:42:30Z","timestamp":1749649350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01515-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01515-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"17 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by scPharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"CPH has no conflicts to disclose. HPF is supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development under award 1T32HD104576. EK and JM are employees of and own stock in scPharmaceuticals, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data are available upon reasonable request by emailing the corresponding author at christoph.hornik@duke.edu.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"CPH developed the analysis plan,\u00a0performed the analyses, and contributed to the interpretation of the findings. HPF contributed to the interpretation of the findings. EK contributed to the study design and study protocol development. JM contributed to the study conceptualization, study design, and interpretation of findings. All authors contributed to the development and critical review of the manuscript and approved the final version for submission.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"This clinical study was conducted according to the principles of the Declaration of Helsinki. The study protocol was approved by the ethical review committee and institutional review board at the participating site.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patients provided written, informed consent before study participation.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}